By improving hemodynamics and reducing NT-proBNP level, Macitentan improved the chance of threshold value reaching and reducing morbidity and mortality irrespective of WHO FC and background PAH-specific therapy [26]. This evidence concerns the gene NPPB and pulmonary arterial hypertension.